Wnt pathway inhibitor (Curegenix)

Triple-negative breast cancer (TNBC) remains the most aggressive breast cancer subtype due to aberrant activation of EMT, predominantly driven by the Wnt/β-catenin signaling. Pigment epithelium-derived factor, a multifunctional protein and negative regulator of the Wnt pathway, is markedly downregulated in TNBC, providing an opportunity to restore the inhibition of this signaling axis for therapeutic benefit. In this study, we present a systematic method for the production of bioactive recombinant pigment epithelium-derived factor protein expressed in Escherichia coli BL21(DE3) and characterized by circular dichroism and MALDI-TOF analyses. Purified rPEDF treatment significantly inhibited the viability and stemness of EMT-induced TNBC cells and 3D spheroids, exhibiting IC₅₀values of 0.15 and 0.11 µM in MDA-MB-231 and MDA-MB-468 monolayer cells, respectively. Mechanistically, rPEDF suppressed p-LRP6 and β-catenin levels, leading to reduced expression of downstream Wnt/β-catenin targets such as c-MYC, cyclin D1 and MMP-7, with synergistic inhibition when combined with a Wnt pathway inhibitor FH535. rPEDF treatment also suppressed the invasion and migratory capability of TNBC cells, with a 1.65-fold and 1.68-fold reduction in MDA-MB-231 and MDA-MB-468 cells, respectively. This effect was accompanied by concomitant downregulation of mesenchymal markers (Slug, Vimentin, Caveolin) and upregulation of epithelial markers, indicating successful reversal of EMT. Additionally, rPEDF treatment elevated intracellular ROS levels, triggering oxidative stress-mediated cytotoxicity in TNBC cells. Overall, our comprehensive findings establish rPEDF as a potent suppressor of EMT and Wnt-driven oncogenic signaling in TNBC, highlighting its promising potential as a recombinant protein to mitigate tumour metastasis and aggressiveness.